Compare Charter Communications Inc (CHTR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs GSK plc — how do they compare? Charter Communications Inc trades at $128 (market cap $15.73B), while GSK plc trades at $51.18 (market cap $101.55B). The key difference: GSK plc is far larger — about 6.5× Charter Communications Inc's market cap, and GSK plc pays a 3.5% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | GSK | |
|---|---|---|
Market Cap | $15.73B | $101.55B |
Sector | Media | Health |
52-Week High | $398.11 | $61.18 |
52-Week Low | $125.54 | $36.20 |
Enterprise Value | $112.04B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $131.37, up 0.49% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The stock appears deeply undervalued with a P/E of 3.55 and EV/EBITDA of 5.3, supported by a 9.03% net income margin and strong cash flow. Recent news highlights potential strategic partnerships with SpaceX and acquisition interest from Comcast, driving investor optimism despite recent earnings misses.
The outlook for CHTR is cautiously optimistic, with significant upside potential based on analyst consensus targets near $196.20. Key opportunities include valuation discount, cash flow inflection, and strategic moves, while risks involve high debt levels, competitive pressures, and execution on subscriber growth. The stock's current level near support at $130 suggests a critical juncture for near-term direction.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
